Australia's most trusted
source of pharma news
Thursday, 07 May 2026
Posted 7 May 2026 AM
The exclusivity of AstraZeneca's Forxiga is under threat after a court ruling allowing Pharmacor to challenge the validity of the patent extension that currently covers the heart and kidney drug.
It's a sizeable market for AstraZeneca, with Forxiga earning $105.5 million in pre-rebate R/PBS reimbursements for the 12 months ending March 2026.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.